Oroxylin A Enhances Sorafenib Sensitivity in Liver Cancer Cells
Author Information
Author(s): Ji Shufan, Xu Xuefen, Li Yujia, Sun Sumin, Fu Qiuyu, Qiu Yangling, Wang Shuqi, Xia Siwei, Wang Feixia, Zhang Feng, Xuan Ji, Zheng Shizhong
Primary Institution: Nanjing University of Chinese Medicine
Hypothesis
Can Oroxylin A enhance the sensitivity of HepG2 cells to sorafenib under hypoxic conditions?
Conclusion
Oroxylin A has the potential to improve the effectiveness of sorafenib treatment for liver cancer by inhibiting mitophagy.
Supporting Evidence
- Oroxylin A significantly improved the inhibitory effect of sorafenib on HepG2 cells.
- Silencing TFAM increased ROS levels and enhanced the sensitivity of HepG2 cells to sorafenib.
- OA reduced TFAM expression, which inhibited mitophagy and restored drug sensitivity.
Takeaway
Oroxylin A helps make liver cancer cells more sensitive to a drug called sorafenib, especially when there isn't enough oxygen.
Methodology
The study used MTT assays, colony formation assays, and a mouse xenograft tumor model to evaluate the effects of Oroxylin A on HepG2 cells.
Limitations
The study exclusively used the HepG2 cell line, which may limit the generalizability of the findings.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website